This Biotech Stock Is Up 100% This Year. Why It's Soaring Again Today

Dow Jones01-16

ImmunityBio stock is on a tear in 2026 and it looks like the biotech company's stellar rally will keep going.

The shares are up 99% this year, as of Thursday close. In fact, they've climbed on every trading day so far in 2026. The streak, and the impressive gain, are set to continue as the stock was pointing another 21% higher ahead of the open Friday.

The catalysts also keep coming. The biotech company said full-year revenue from its bladder cancer drug ANKTIVA was set to surge 700% year-over-year to $113 million, in its preliminary earnings results Thursday. Earlier this week Immunitybio said the Saudi Food and Drug Authority has approved ANKTIVA for the treatment of patients with non-small cell lung cancer.

Just five analysts cover the stock, according to FactSet data, but they have an average price target of $10.40, implying a 163% upside to Thursday's closing price.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603967590?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-16 19:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603967590","market":"sg","top_or_hot":-1,"title":"This Biotech Stock Is Up 100% This Year. Why It's Soaring Again Today","media":"Dow Jones","content":"<html><head></head><body><p>ImmunityBio stock is on a tear in 2026 and it looks like the biotech company&#39;s stellar rally will keep going.</p><p>The shares are up 99% this year, as of Thursday close. In fact, they&#39;ve climbed on every trading day so far in 2026. The streak, and the impressive gain, are set to continue as the stock was pointing another 21% higher ahead of the open Friday.</p><p>The catalysts also keep coming. The biotech company said full-year revenue from its bladder cancer drug ANKTIVA was set to surge 700% year-over-year to $113 million, in its preliminary earnings results Thursday. Earlier this week Immunitybio said the Saudi Food and Drug Authority has approved ANKTIVA for the treatment of patients with non-small cell lung cancer.</p><p>Just five analysts cover the stock, according to FactSet data, but they have an average price target of $10.40, implying a 163% upside to Thursday&#39;s closing price.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Biotech Stock Is Up 100% This Year. Why It's Soaring Again Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Biotech Stock Is Up 100% This Year. Why It's Soaring Again Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-16 19:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>ImmunityBio stock is on a tear in 2026 and it looks like the biotech company&#39;s stellar rally will keep going.</p><p>The shares are up 99% this year, as of Thursday close. In fact, they&#39;ve climbed on every trading day so far in 2026. The streak, and the impressive gain, are set to continue as the stock was pointing another 21% higher ahead of the open Friday.</p><p>The catalysts also keep coming. The biotech company said full-year revenue from its bladder cancer drug ANKTIVA was set to surge 700% year-over-year to $113 million, in its preliminary earnings results Thursday. Earlier this week Immunitybio said the Saudi Food and Drug Authority has approved ANKTIVA for the treatment of patients with non-small cell lung cancer.</p><p>Just five analysts cover the stock, according to FactSet data, but they have an average price target of $10.40, implying a 163% upside to Thursday&#39;s closing price.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603967590","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603967590","pubTimestamp":1768562891,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"ImmunityBio stock is on a tear in 2026 and it looks like the biotech company's stellar rally will keep going.The shares are up 99% this year, as of Thursday close. In fact, they've climbed on every trading day so far in 2026. The streak, and the impressive gain, are set to continue as the stock was pointing another 21% higher ahead of the open Friday.The catalysts also keep coming. The biotech company said full-year revenue from its bladder cancer drug ANKTIVA was set to surge 700% year-over-year to $113 million, in its preliminary earnings results Thursday. Earlier this week Immunitybio said the Saudi Food and Drug Authority has approved ANKTIVA for the treatment of patients with non-small cell lung cancer.Just five analysts cover the stock, according to FactSet data, but they have an average price target of $10.40, implying a 163% upside to Thursday's closing price.This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc.","BK4139":"生物科技"},"translate_title":"这只生物科技股今年上涨了100%。为什么今天又飙升了。——Barrons.com","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":0.9},"content_text":"ImmunityBio stock is on a tear in 2026 and it looks like the biotech company's stellar rally will keep going.The shares are up 99% this year, as of Thursday close. In fact, they've climbed on every trading day so far in 2026. The streak, and the impressive gain, are set to continue as the stock was pointing another 21% higher ahead of the open Friday.The catalysts also keep coming. The biotech company said full-year revenue from its bladder cancer drug ANKTIVA was set to surge 700% year-over-year to $113 million, in its preliminary earnings results Thursday. Earlier this week Immunitybio said the Saudi Food and Drug Authority has approved ANKTIVA for the treatment of patients with non-small cell lung cancer.Just five analysts cover the stock, according to FactSet data, but they have an average price target of $10.40, implying a 163% upside to Thursday's closing price.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603967590","isCrawlerRequest":true}